α 2-Antiplasmin plays a significant role in acute pulmonary embolism

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 8, 2003, Pages 1734-1739

  Matsuno, H ^a   Okada, K ^b   Ueshima, S ^b   Matsuo, O ^b   Kozawa, O ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrinolytic components; Pulmonary embolism; Thromboembolism; Venous thrombus

Indexed keywords

ANTIPLASMIN; FIBRINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ANIMAL; ARTICLE; BIOSYNTHESIS; BLEEDING TIME; JUGULAR VEIN; LUNG; LUNG EMBOLISM; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; TIME; TRANSGENIC MOUSE; VEIN THROMBOSIS;

ACUTE DISEASE; ANIMALS; ANTIPLASMIN; BLEEDING TIME; FIBRINOGEN; JUGULAR VEINS; LUNG; MICE; MICE, TRANSGENIC; PULMONARY EMBOLISM; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS;

EID: 2142707127     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00252.x     Document Type: Article

References (36)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
2. Sutton GC, Hall RJ, Kerr IH. Clinical course and late prognosis of treated subacute massive, acute minor, and chronic pulmonary thromboembolism. Br Heart J 1997; 10: 1135-42.
3. Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Buller HR. Travel and risk of venous thrombosis. Lancet 2000; 356: 1492-3.
4. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
5. Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P. Growth factor control of extracellular proteolysis. Cell Differ Dev 1990; 32: 313-8.
6. Matsuno H, Kozawa O, Niwa M. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81: 601-4
7. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasmino-gen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
8. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequence of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
9. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97: 1002-8.
10. Kawasaki T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts ME. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000; 96: 153-60.
11. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vase Biol 1999; 19: 2801-6.
12. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
13. Wiman B, Collen D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem 1979; 254: 9291-7.
14. Bayes-Genis A, Guindo J, Oliver A, Badimon L, Fiol M, Mateo J, Souto JC, Dominguez JM, Fontcuberta J, Bayes de Luna A. Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina. Thromb Haemost 1999; 81: 865-8.
15. Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T. Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice. Thromb Haemost 2000; 83: 605-9.
16. Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelet thrombus formation in mice. Br J Pharmacol 2000; 131: 858-64.
17. Nishida M, Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein Ilb/IIIa antagonist, but not by a factor Xa inhibitor. J Cardiovasc Pharmacol 2000; 36: 770-5.
18. Okada K, Lijnen HR, Dewerchin M, Belayew A, Matsuo O, Collen D, Bernaerts R. Characterization and targeting of the murine alpha2-antiplasmin gene. Thromb Haemost 1997; 78: 1104-10.
19. Gulledge AA, Rezaee F, Verheijen JH, Lord ST. A novel transgenic mouse model of hyperfibrinogenemia. Thromb Haemost 2001; 86: 511-6.
20. Bdeir K, Murciano JC, Tomaszewski J, Koniaris L, Martinez J, Cines DB, Muzykantov VR, Higazi AA. Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood 2000; 96: 1820-6.
21. Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P, Page CP, Gresele P. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacol 2000; 397: 177-85.
22. Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000; 102: 1151-7.
23. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost 2001; 86: 444-51.
24. Menoud PA, Sappino N, Boudal-Khoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest 1996; 97: 2478-84.
25. Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice. Blood Coagul Fibrinolysis 2000; 11: 645-55.
26. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Okada K, Ueshima S, Matsuo O, Uematsu T. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002; 100: 2487-93.
27. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 2001; 86: 640-6.
28. Lee KN, Tae WC, Jackson KW, Kwon SH, McKee PA. Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant. Blood 1999; 94: 164-71.
29. Agnelli G, Buchanan MR, Fernandez F, Boneu B, Van Ryn J, Hirsh J, Collen D. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178-82.
30. Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1983; 7: 368-76.
31. Matsuno H, Uematsu T, Nakashima M. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. Br J Pharmacol 1993; 110: 1278-9.
32. Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood 1982; 59: 1169-80.
33. Aoki N, Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin ChimActa 1978; 84: 99-105.
34. Teger-Nilsson AC, Gyzander E, Myrwold H, Noppa H, Olsson R, Wallmo L. Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. Haemostasis 1978; 7: 155-7.
35. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43-8.
36. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thromb Haemost 2002; 87: 98-104.